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Abstract
The amyloid precursor protein (APP) takes a central position in Alzheimer's disease (AD)
pathogenesis: APP processing generates the β-amyloid (Aβ) peptides, which are deposited as the
amyloid plaques in brains of AD individuals; Point mutations and duplications of APP are causal for
a subset of early onset of familial Alzheimer's disease (FAD). Not surprisingly, the production and
pathogenic effect of Aβ has been the central focus in AD field. Nevertheless, the biological
properties of APP have also been the subject of intense investigation since its identification nearly
20 years ago as it demonstrates a number of interesting putative physiological roles. Several
attractive models of APP function have been put forward recently based on in vitro biochemical
studies. Genetic analyses of gain- and loss-of-function mutants in Drosophila and mouse have also
revealed important insights into its biological activities in vivo. This article will review the current
understanding of APP physiological functions.
Background
Alzheimer's disease (AD) is the most common cause of
dementia occurring in the elderly. It is characterized path-
ologically by the deposition of β-amyloid plaques, the
accumulation of neurofibrillary tangles and loss of neu-
rons and synapses in selected areas of the brain. The β-
amyloid plaques are extracellular deposits of heterogene-
ous substances of which the major components are 40 to
42 amino acid peptides referred to as β-amyloid peptides
(Aβ) that are derived by proteolytic cleavages of the amy-
loid precursor protein (APP). Liberation of Aβ from APP
requires the action of β- and γ-secretases which process
APP at amino-terminus and carboxyl-terminus of the Aβ
sequence, respectively (reviewed in [1,2]). Approximately
5–10% of AD cases are familial and cosegregate with auto-
somal dominant inheritance of mutations in APP [3] and
two homologous molecules, presenilin 1 (PS1) [4] and
presenilin 2 (PS2) [5] (up-to-date genetic mutations can
be found at http://www.alzforum.org). PS1 or PS2 is a
necessary component of the high molecular weight com-
plex indispensable for γ-secretase processing of APP. The
familial AD (FAD) mutations in the presenilin genes are
known to subtly alter the γ-secretase activity to perturb
APP proteolysis (reviewed in [6]). This biochemical and
genetic evidence places APP and its processing steps in a
central position in AD research.
This review focuses on the physiological properties of
APP. We start with a general overview of APP, including its
family members, expression patterns and processing char-
acteristics. Because APP consists of multiple structural and
functional domains, we will focus our review by address-
ing the properties of the APP ectodomain and the intrac-
ellular domain. Finally, we provide an update on the
current knowledge concerning the APP function in vivo.
Understanding the biology of APP is not only interesting
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from an intellectual point of view, but also of immediate
relevance to AD pathogenesis. Because Aβ is generated as
part of the normal APP processing, deregulation of Aβ
production is expected to simultaneously affect other APP
processing metabolites and perhaps APP regulated path-
ways. As such, perturbation of normal APP physiology
may contribute to AD pathogenesis in an Aβ dependent or
independent manner. The pathophysiology of Aβ, which
has been the focal point of AD research for the past two
decades, has been extensively discussed and is beyond the
scope of this review.
I. APP: an overview
a) The APP family
APP is a member of a family of conserved type I mem-
brane proteins including APL-1 in C. elegans [7], APPL in
Drosophila  [8,9] and APP [10,11], APP like protein 1
(APLP1) [12] and 2 (APLP2) [13,14] in mammals
(reviewed in [15]) (Figure 1). These proteins share several
conserved motifs, including the E1 and E2 domains in the
extracellular sequences and the intracellular domain, the
latter exhibits the highest sequence identity. Of interest,
the Aβ peptide domain is not conserved and is unique to
APP. However, the mammalian APP homologs play
redundant activities in vivo (discussed in "The in vivo
Function of APP"). The functional conservation of the
APP across species is documented by the partial rescue of
the Drosophila APPL null behavioral phenotype by human
APP [16]. These observations indicate that the conserved
motifs, rather than the Aβ sequence, likely underlie the
conserved physiological functions among the APP species.
b) APP expression
Mammalian APP family of proteins is abundantly
expressed in the brain. Similar to Drosophila APPL [17],
APLP1 expression is restricted to neurons [18]. However,
although highly enriched in the brain, APP and APLP2 can
be detected in most other tissues as well. The human APP
gene, located on the long arm of chromosome 21, spans
approximately 240 kb and contains at least 18 exons
[19,20]. Alternative splicing generates APP mRNAs encod-
ing several isoforms that range from 365 to 770 amino
acid residues. The major Aβ peptide encoding proteins are
695, 751, and 770 amino acids (referred to as APP695,
APP751 and APP770). APP751 and APP770 contain a
domain homologous to the Kunitz-type serine protease
inhibitors (KPI) in the extracellular sequences, and these
isoforms are expressed in most tissues examined. APP695
isoform lacks the KPI domain and is predominately
expressed in neurons [21]. The reason and functional sig-
nificance for this apparent tissue-specific alternative splic-
ing is poorly understood.
c) APP processing
APP undergoes constitutive secretory pathway and is post-
translationally modified in route by N- and O-glycosyla-
tion, phosphorylation and tyrosine sulphation (reviewed
in [2]). Full-length APP is sequentially processed by at least
three proteinases termed α-, β- and γ-secretases (Figure 2).
Cleavage by α-secretase or β-secretase within the luminal/
extracellular domain results in the shedding of nearly the
entire ectodomain to yield large soluble APP derivatives
(called APPsα and APPsβ respectively) and generation of
membrane-tethered  α- or β-carboxyl-terminal fragments
(CTFs). The major neuronal β-secretase is a transmem-
brane aspartyl protease, termed BACE1 (β-site APP cleav-
ing enzyme) [22-24]. Several zinc metallopreoteinases,
including TACE/ADAM17, ADAM9, ADAM10 and MDC-
9, and an aspartyl protease BACE2 can cleave APP at the α-
secretase site located within the Aβ domain (Figure 2)
(reviewed in [25]), essentially precluding the generation of
intact Aβ. Following the extracellular cleavages, γ-secretase
processes APP at the carboxyl-terminus of Aβ, producing
either a 3 kDa product (p3 in combination with the α-
secretase) or Aβ (in concert with BACE1 cleavage), respec-
tively, and the APP intracellular domain (AICD). The γ-
secretase activity is primarily executed by a high molecular
weight complex containing at least presenilin, nicastrin,
anterior pharynx defective (APH1) and presenilin
enhancer (PEN2) (reviewed in [6,26]). However, the list of
γ-secretase components may be expanding as other new
molecules are being identified [27]. These processing
events occur in various organelles and also on cell surface.
In neurons, APP is anterogradely transported along the
axons and is proteolytically processed during transit ([28-
30], also discussed below). In non-neuronal cells, APP that
reaches to plasma membrane is internalized within min-
utes through the conserved YENPTY motif (Figure 1) [31].
Following endocytosis, APP is delivered to late endosomes
or can be recycled back to cell surface [32].
II. The APP ectodomain
Various subdomains can be assigned to the APP extracel-
lular sequences based on its primary sequences and struc-
tural studies (reviewed in [33,34]). These include the E1
domain, which consists of the N-terminal growth factor-
like domain (GFLD) and the metal (copper and zinc)
binding motif, the Kunitz-type protease inhibitor (KPI)
domain present in APP751 and APP770 isoforms, the E2
domain which include the RERMS sequence and the extra-
cellular matrix components (heparin, collagen, and lam-
inin). We address below the functional studies associated
with the APP extracellular domain.
a) Cell surface receptor
The analogy of the secondary structures and proteolytic
processing profiles between Notch and APP predicts that
APP could function as a cell surface receptor similar toMolecular Neurodegeneration 2006, 1:5 http://www.molecularneurodegeneration.com/content/1/1/5
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Notch (reviewed in [35]). Supporting this hypothesis,
Bruce Yankner's group reported that the β-amyloid pep-
tide could bind to APP and thus could be a candidate lig-
and for APP [36]. Another piece of evidence came from
Ho and Sudhof (2004) which showed that APP extracellu-
lar domain bind to F-spondin, a neuronally secreted glyc-
oprotein, and this interaction regulates Aβ production
and downstream signaling [37]. Similarly, the Nogo-66
Amino acid sequence alignment of C. elegans APL-1, Drosophila APPL and human APP, APLP1 and APLP2 Figure 1
Amino acid sequence alignment of C. elegans APL-1, Drosophila APPL and human APP, APLP1 and APLP2. Identical sequences 
are shaded in green and conserved changes in light blue. The E1 and E2 domains are shown in purple and orange underlines 
respectively. Yellow bracket denotes the transmembrane domain, the Aβ sequences is outlined within the red bracket, and the 
Thr668 residue and the YENPTY sequence are marked by the asterisk and filled squares underneath the sequences respectively.
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receptor was recently shown to interact with the APP ecto-
domain and by which means affect Aβ production [38].
Finally, the fact that the extracellular domains of the APP
family of protein could potentially interact in trans (dis-
cussed below) suggest that APP molecules can interact in
a homophilic manner. However, while the concept is
appealing, the evidence that APP could function as a bona
fide surface receptor remains speculative.
b) Cell adhesion
Data linking cell surface APP in cell-substratum and cell-
cell adhesion are perhaps more convincing. The E1 and E2
regions have been shown to interact with extracellular
matrix proteins and heparan sulfate proteoglycans
(reviewed in [39]), supporting its role in cell-substratum
adhesion. The same sequences have also been implicated
in cell-cell interactions. Specifically, X-ray analysis
revealed that the E2 domain of APP could form antiparal-
lel dimers [40]. Such a structure has the potential to func-
tion in trans-cellular adhesion. Cell culture studies
support the homo- or hetero-dimer formation of the APP
family members, and the trans-dimerizations have been
shown to promote cell-cell adhesion [41]. However, this
activity appears to be mediated by the E1 domain. Down-
stream of the E1 and E2 regions, a "RHDS" motif in the
extracellular domain of APP within the Aβ sequence also
appears to promote cell adhesion. It is believed that this
region acts in an integrin-like manner by homology to the
"RGD" sequence [42]. In this regard, it is interesting that
APP colocalizes with integrins on the surface of axons and
at sites of adhesion [43,44].
c) Neurite outgrowth and synaptogenesis
A neurotrophic and synaptogenic role for APP is perhaps
the most consistently documented and arguably the best
established, and this function may be linked to its adhe-
sive properties described above. A number of publications
have pointed to an important role of the APP extracellular
domain in this activity, both as a full-length protein and
as a secreted molecule (APPs) following ectodomain
shredding. Thus, APP may exert these activities in both
autocrine and paracrine fashions. APP expression is
upregulated during neuronal maturation and differentia-
tion [45,46]. Its expression is also induced during trau-
matic brain injury both in mammals and in Drosophila
[47-50]. APP undergoes rapid anterograde transport and
is targeted to the synaptic sites [21,29,51,52], where the
levels of secreted APP coincide with synaptogenesis [53].
The crystal structure of the E1 domain shows similarities
to known cysteine-rich growth factors that it is thus
termed as the growth factor-like domain (GFLD) [54].
One of the earliest indications of APP function came from
the observation that assessing fibroblasts treated with an
antisense APP construct grew slower and the growth retar-
dation can be restored by treatment with secreted APPs
[55]. The active domain was subsequently mapped to a
pentapeptide motif "RERMS" in the E2 domain [56]. The
Schematic diagram of APP sequential processing (not drawn in scale) Figure 2
Schematic diagram of APP sequential processing (not drawn in scale). EC: extracellular; TM: transmembrane; IC: intracellular. 
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activity is not limited to fibroblasts as infusion of this pen-
tapeptide or APPs into brain resulted in increased synaptic
density and improved memory retention in animals
[57,58], while injection of APP antibodies directly into
the brain led to impairment in behavioral tasks in adult
rat [57]. This finding is corroborated by reports showing
that reduction of APP is associated with impaired neurite
outgrowth and neuronal viability in vitro and synaptic
activity in vivo [59-61]. A recent paper further substanti-
ated this finding, showing that the growth promoting
property is mediated by the ability of APPsα to down-reg-
ulate CDK5 and inhibit tau hyperphosphorylation [62].
Finally, Caille et al. indicated the presence of binding sites
for APPs in epidermal growth factor (EGF)-responsive
neural stem cells in the subventricular zone in the adult
rodent brain [63]. In this context, APPsα acts as a co-factor
with EGF to stimulate the proliferation of these cells both
in neurospheres in culture and in vivo. Because APPs lev-
els have been reported to be reduced in individuals with
AD [64], this result raises the possibility that the loss of
the trophic activity of APPs, in concert with the reduction
of other growth factors in the brain, may contribute to the
neurodegeneration in AD.
III. The APP intracellular domain
The high degree of sequence conservation between the
intracellular domain of APP, APLP1, and APLP2 predicts
that it is a critical domain regulating APP function.
Indeed, multiple important roles have been assigned to
this domain, most notably in axonal transport and cell
signaling.
a) Phosphorylation and protein-protein interaction
APP can be phosphorylated at multiple sites in both extra-
cellular and intracellular domains [65]. Among these, the
phosphorylation at the threonine residue (Thr668) in APP
intracellular domain (Figure 1) has received most of the
attention to date. Several kinases have been implicated in
this phosphorylation event, including the cyclin-depend-
ent kinase 5 (CDK5), c-Jun N-terminal kinase 3 (JNK3),
and GSK3β [66-68]. This phosphorylation has been
implicated to regulate APP localization to the growth
cones and neurites [68,69]. Significantly, the Thr668 phos-
phorylated APP is shown to be preferentially transported
to the nerve terminals [70], and that the Thr668 phospho-
rylated APP fragments are increased in AD, but not in con-
trol subjects [71], raising the possibility that this
phosphorylation event may contribute to AD pathogene-
sis by regulating Aβ generation in neurons. A recent work
provided a possible link between Thr668 phosphorylation
and APP processing through the prolyl isomerase Pin1.
The authors showed that Pin1 binds to the phosphor-
ylated Thr668-Pro motif and promotes the isomerization
of the proline residue [72]. This leads to the conforma-
tional change of the APP intracellular domain and altera-
tion of APP processing and Aβ production.
In addition to Thr668 phosphorylation, the highly con-
served APP intracellular domain has been shown to bind
to numerous proteins (reviewed in [73,74]). Of particular
interest and relevance to this review, the YENPTY motif is
required to interact with various adaptor proteins, includ-
ing Mint-1/X11a (and the family members Mint-2 and
Mint-3, so named for their ability to interact with
Munc18), Fe65 (as well as Fe65 like proteins Fe65L1 and
Fe65L2) and c-Jun N-terminal kinase (JNK)-interacting
protein (JIP), through the phosphotyrosine-binding
(PTB) domain. Interestingly, the APP Thr668 phosphoryla-
tion and adaptor protein interaction may be functionally
coupled. Biochemical and structural studies indicate that
Thr668  phosphorylation results in a conformational
change which negatively regulates APP binding to Fe65
and reduces the stability of the APP intracellular domain
[67,75,76]. This phosphorylation has also been reported
to modulate APP interaction with Mint-1/X11a [77].
Overall, these findings lend support for an important role
of Thr668 phosphorylation and Fe65 and/or Mint-1/X11a
in regulating APP dynamics. Of interest is the finding that
Fe65 acts as a functional linker between APP and LRP
(another type I membrane protein containing two NPXY
endocytosis motifs) in modulating endocytic APP traffick-
ing and amyloidogenic processing [78].
b) Cell migration and synapse remodeling
In addition to stabilizing AICD and modulating nuclear
signaling, the binding of APP with Fe65 has been impli-
cated in regulating cell motility and growth cone dynam-
ics [79,80]. In H4 neuroglioma and MDCK cells, APP is
found to associate with Fe65 and mammalian homolog of
Enabled (Mena), a cytoskeletal protein expressed in active
actin remodeling areas such as lamellipodia and growth
cones (reviewed in [81]). The functional role of this com-
plex is documented in a wound healing assay in MDCK
cells in which the authors showed increased rate of cell
migration and wound closure by overexpressing APP and
Fe65, and this process appears to be partially dependent
on Mena/actin complex [79]. Subsequent analysis by the
same group showed that in primary neurons, APP and
Fe65 are concentrated in actin-rich area of the growth
cones, supporting an active role of the APP/Fe65 complex
in growth cone dynamics and synapse remodeling [80].
Indeed, a physiological significance of the APP/Fe65 inter-
action is supported by loss-of-function studies in mice
and in C. elegans (discussed in "The in vivo Function of
APP).
APP also interacts with Mint/X11 family of proteins
through the same YENPTY motif. Using Drosophila as a
model system, it was shown that APPL was required toMolecular Neurodegeneration 2006, 1:5 http://www.molecularneurodegeneration.com/content/1/1/5
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facilitate cell adhesion molecule fasciclin-mediated syn-
apse formation at Drosophila neuromuscular junction, and
this process involved the interaction with dMint [82].
How these adaptor proteins are coordinated to contribute
to various APP processes is not clear and needs to be fur-
ther studied.
c) Cell signaling
In addition to the γ-cleavage that yields Aβ 40 and Aβ 42,
PS-dependent proteolysis also occurs at other positions
including the ε-site (Aβ 49) downstream of the γ-site prox-
imal to the membrane-intracellular boundary [83-85].
Recent data provide support for a sequential cleavage
model in which ε-cleavage serves as the initial cutting site
followed by δ- and γ-processing within the membrane
[85-87]. Thus the ε-cleavage of APP may represent the pri-
mary PS-dependent processing event. This is important
because this cleavage releases an APP intracellular domain
(AICD) that is highly reminiscent of the release of the
Notch intracellular domain (NICD) after γ-secretase
processing, the latter being an obligatory step in Notch
mediated signaling (reviewed in [35]). Accordingly, PS-
dependent AICD has been shown to translocate to
nucleus and could function as a transcriptional regulator
[88-90]. AICD is very labile but can be stabilized by Fe65
[88]. Using a heterologous reporter system, AICD is
shown to form a transcriptionally active complex presum-
ably in the nucleus together with Fe65 and Tip60 [89,91].
However, subsequent analyses have suggested that the
earlier view may be too simplistic and incomplete. First,
follow up studies by Cao et al. showed that nuclear trans-
location of AICD is not required but may be indirect
through Fe65 [92]; secondly, PS-dependent AICD produc-
tion is not required for the APP signaling activity as it pro-
ceeds normally in PS null cells and by PS inhibitor
treatment [93]. Instead, the authors provide an alternative
pathway for this activity that involves Tip60 phosphoryla-
tion. Lastly, a recent report documented that the proposed
signaling activity is executed by Fe65 and that APP is not
required altogether [94]. Overall, a potential nuclear sign-
aling activity remains to be established.
In spite of the unclear nature of how AICD may activate
signaling pathways, a trans-activating role of the APP/
Fe65/Tip60 complex has been consistently documented,
at least in overexpression systems. Accordingly effort has
been taken to identify the downstream targets. Two genes
have been proposed to date, KAI1, a tumor suppressor
gene, and neprilysin, a neutral endopeptidase with Aβ
degrading activity [95,96]. The latter pathway is particu-
larly interesting because it suggests that γ-secretase release
of AICD can regulate the degradation of Aβ in the extracel-
lular space. If this is true, it will be important to know the
feedback pathways that modulate γ-secretase activity to
regulate neprilysin expression. The proposed AICD signal-
ing has also been implicated in phosphoinositide-medi-
ated calcium signaling and cell cycleregulation ([97] and
reviewed in [98]). Specifically, fibroblast cells lacking APP
exhibit calcium signaling defect which can be rescued by
expressing AICD, and the aforementioned CDK5 and
Pin1 that interact and regulate the APP intracellular
domain are linked to cell cycle events.
d) Apoptosis
The preceding sections have highlighted the positive or
beneficial functions of APP. Interestingly, there is a rather
lengthy history of cytotoxic properties of APP, especially
when APP or the β-cleaved C-terminal fragment of APP
("C99" or "C100") are overexpressed [99,100]. Indeed,
overexpression of the C100 APP C-terminal fragment
(CTF) is associated with neuronal degeneration in brain
[101], perhaps by perturbing APP signal transduction.
Another pathway by which the APP CTF is cytotoxic may
be through AICD. Specifically, the cytotoxicity of APP CTF
appears to require an intact caspase site within the
cytosolic tail [102]. In this cell culture model, loss of this
caspase site by mutating the aspartate residue at position
664 to alanine (D664A) resulted in a loss of C100 associ-
ated cytotoxicity. It has been proposed that release of the
smaller fragments (C31 and Jcasp) from AICD after cleav-
age at position 664 results in the generation of new cyto-
toxic APP related peptides [103]. Indeed, in an APP
transgenic mouse line in which the caspase site is mutated
to render APP noncleavable, the predicted Aβ-related phe-
notypes in brain, including synaptic, behavior, and elec-
trophysiological abnormalities, were absent in spite of
abundant amyloid deposits in brain [104]. Therefore,
release of the smaller fragments (C31 or Jcasp) after cas-
pase cleavage of C99 may result in activation of genes that
contribute to cell death in a manner independent of γ-
secretase. Therefore, there are at present several potential
mechanisms whereby APP may contribute to neurotoxic-
ity: via γ-secretase cleavage to release AICD or via alterna-
tive cleavage of the APP C-terminus to release other
cytotoxic peptides.
e) Axonal transport
The neuron is unique in cellular morphology with a long
axon and a rich dendritic arbor. Elaborate protein traffick-
ing exists in neurons for selected proteins to reach their
designated compartments and to be transported back to
the cell bodies. Protein processing and modifications are
known to take place during the transit in axons. APP is
transported in axons via the fast anterograde transport
machinery, a process that requires kinesin molecular
motors, and that at least one documented source of amy-
loid deposits originates from synaptically released Aβ
pool [105,106]. The anterograde transport of APP is pro-
posed to be mediated by binding of APP with kinesin light
chain (KLC) subunit, a component of the kinesin-1 trans-Molecular Neurodegeneration 2006, 1:5 http://www.molecularneurodegeneration.com/content/1/1/5
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port machinery [107]. However, recent evidence is more
consistent with the view that the interaction is mediated
indirectly through adaptor proteins, of which JIP-1, a
member of the JNK-interacting protein family (JIP), is a
likely candidate as it is known to interact with both KLC
and APP [108]. The fact that either deletion or overexpres-
sion of the Drosophila APP homolog, APPL, in Drosophila
neurons disrupts axonal transport, a phenotype similar to
that seen in flies lacking components of the kinesin motor
[109,110], prompted Goldstein and colleagues to pro-
pose that APP may represent a kinesin cargo receptor,
linking kinesin-1 to a unique subset of transport cargos.
This model is consistent with the observation that the car-
gos that carry APP anterogradely in axons are different
from the transport carrier of synaptophysin [111].
Unresolved by this model is how APP is initially sorted
into a particular class of vesicles. The potential impor-
tance of the initial sorting of APP is underscored by the
report that BACE1 and presenilins are contained within
the same kinesin-1 dependent APP transport vesicles [30].
This finding led to the suggestion that not only is APP
required for the delivery of the enzymatic machinery nec-
essary for Aβ production, but Aβ generation also occurs
enroute from the cell body to the nerve terminals within
the transport cargo that is carried by APP. However, the
report that APP is a kinesin-1 receptor and a common
vesicular compartment carried all the processing machin-
ery necessary for Aβ generation have not been confirmed
by others [112]. Nevertheless, KLC deficient animals,
when crossed with APP transgenic mice, showed axonal
pathology manifested by axonal swellings and increased
amyloid levels and deposits in brain [113]. The latter
argue that perturbations of axonal transport during aging
may predispose to the development of AD pathology.
IV. In vivo function of APP
The in vivo gain- and loss-of-function phenotypes associ-
ated with the APP family of proteins in model systems (C.
elegans, Drosophila and mice) are consistent with a role of
APP in neuronal and synaptic function in both central and
peripheral nervous systems. This may involve the APP
ectodomain, the APP intracellular domain, the Aβ
sequence or, indeed, the cross communications among
these motifs. These findings will be discussed next in the
respective animal models.
a) C. elegans
Although the cloning of the C. elegans APP homolog APL-
1 was published in 1993 [7], to date there has been no
report describing the APL-1 null mutant. Using RNA-inter-
ference (RNAi) method, Zambrano et al. reported that
worms treated with APL-1 RNAi exhibit defect in pharyn-
geal pumping and, interestingly, this phenotype is shared
with Fe65 homolog-1 (Feh-1) treated worms [114], sug-
gesting that these two proteins act in the same pathway
possibly through direct physical interactions. Of note, the
C. elegans pharynx is a cholinergic neuromuscular struc-
ture that uses acetylcholine as a neurotransmitter. A possi-
ble role of the APL-1/Feh-1 complex in regulating the
cholinergic function is provided by the same group show-
ing that mutation in Feh-1 results in a reduction of acetyl-
cholinesterase gene expression [115]. Because our own
studies document an indispensable activity of the APP
family of proteins in regulating cholinergic neurotrans-
mission at the neuromuscular junction (NMJ) ([116], and
see below), these findings taken together support a con-
served role of APP family of proteins in cholinergic path-
way possibly in a Fe65 dependent manner.
b) Drosophila
Drosophila  mutants lacking APPL are viable, fertile but
exhibit subtle behavioral defects that can be partially res-
cued by human APP, demonstrating functional conserva-
tion [16]. Subsequent analysis revealed that these mutant
flies show reduced synaptic bouton numbers at neu-
romuscular junction [117], and that this activity appears
to require the formation of a complex with the cell adhe-
sion molecule fasciclin and Drosophila  Mint/X11 [82].
Consistent with a role of APPL in synapse development,
ectopic overexpression of APPL leads to satellite bouton
formation at Drosophila NMJ, and this activity requires the
APP YENPTY domain where adaptor protein interaction
takes place [117].
Similar gain-of-function studies in Drosophila revealed a
spectrum of other phenotypes, ranging from a blistered
wing phenotype that may involve cell adhesion [118], a
Notch gain-of-function phenotype in mechano-sensory
organs, which reveals a possible genetic interaction of APP
and Notch through Numb [119], and a neurite outgrowth
phenotype that is linked to the Abelson tyrosine kinase
and JNK stress kinase [50]. Although the pathways impli-
cated in each of the phenotypes are distinct, they all seem
to require the APP intracellular domains and protein-pro-
tein interactions through the conserved YENPTY
sequence. These ectopic overexpression studies should be
interpreted with caution though as APP interacts with
numerous adaptor proteins through the YENPTY motif
and many of the APP binding partners also interact with
other proteins. Therefore, the phenotypes observed by
overexpressing APP or APPL could be caused by the distur-
bance of a global protein-protein interaction network.
Interestingly, similar to the mammalian system, APPL is
found to be upregulated in traumatic brain injury [50],
supporting a potential activity of APP family of proteins in
nerve injury response and repair. However, the functional
significance of this nerve injury response remains poorly
understood.Molecular Neurodegeneration 2006, 1:5 http://www.molecularneurodegeneration.com/content/1/1/5
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c) Mice
To understand the in vivo function of APP and its process-
ing products, we generated an APP null mutation in mice
[120]. Homozygous APP deficient mice are viable and fer-
tile. However, the mutant animals were smaller (15–20%
less body weight) than age-matched controls and exhib-
ited decreased locomotor activity and forelimb grip
strength, indicating compromised neuronal or muscular
function. In addition, the majority of the mice show reac-
tive gliosis, suggesting undefined neuronal damage in
brain activity. Indeed, subsequent analysis reveal that
these mice exhibit behavioral deficit in Morris water maze
task [121,122], and are also defective in long-term poten-
tiation and GABA-mediated postsynaptic response [123].
However, these impairments were not caused by a gross
loss of neurons or synapses because unbiased stereologi-
cal quantification failed to detect any loss of neurons or
synaptic bouton numbers in aged APP null mice [122].
The relatively subtle phenotype of the APP deficient mice
indicated that the presence of other APP family members
may compensate for the loss of APP. Indeed, while the
APLP1 and APLP2 single null mice are also viable and fer-
tile,  APP/APLP2,  APLP1/APLP2  double knockout mice
showed early postnatal lethality [124,125]. Intriguingly,
the APP/APLP1 double null mice are viable [125], reveal-
ing a property of APLP2 that is uniquely required when
APP or APLP1 is absent.
In the peripheral nervous system, APP/APLP2  double
knockout animals exhibited poorly formed neuromuscu-
lar junction (NMJ) with reduced apposition of pre- and
postsynaptic elements of the junctional synapses [116].
The number of synaptic vesicles at the presynaptic termi-
nals were also reduced, a finding confirmed by defective
neurotransmitter release. With knowledge of the NMJ
phenotypes of APP/APLP2  double knockout mice in
mind, examination of the parasympathetic submandibu-
lar ganglia of these animals also showed a reduction in
active zone size, synaptic vesicle density, and number of
docked vesicles per active zone [126]. The NMJ pheno-
types in APP/APLP2 null mice are in some aspect similar
but in others distinct from APPL null Drosophila, as the lat-
ter exhibits a subtle reduction of synaptic bouton num-
bers without structural alterations [117]. Furthermore,
while the major synaptic phenotype can be seen when
APPL is overexpressed [82,117], no NMJ defect can be
detected in transgenic mice overexpressing human APP
(HZ, unpublished data).
Deficiency of all three APP genes led to death shortly after
birth. The majority of the animals showed cortical dyspla-
sia, suggestive of migrational abnormalities of the neu-
roblasts and partial loss of cortical Cajal Retzius cells
[127]. Interestingly, this defect is phenocopied in mice
doubly deficient in APP binding proteins Fe65 and
Fe65L1 [128]. This result is consistent with the aforemen-
tioned C. elegans studies, all supporting a common physi-
ological activity of the APP/Fe65 complex. It should be
pointed out, however, that morphological similarity does
not necessarily implicate functional interaction. Indeed,
cortical dysplasia with variable penetrance also exists in
mice deficient in various other proteins including PS1, β1
and α6 integrins, focal adhesion kinase, α-dystroglycan
and laminin α2 (reviewed in [129]).
Taken together, the recent findings presented a convincing
picture that members of the APP gene family play essen-
tial roles in the development of the nervous system relat-
ing to synapse structure and function, as well as in
neuronal migration or adhesion. Whether these abnor-
malities underlie the early postnatal survival of the ani-
mals remain to be established. Further, whether these
activities are due to mechanical properties or mediated by
activating signaling pathways, or both, are interesting
questions that remain to be elucidated.
Concluding remark
This review has examined some of the physiological func-
tions of APP, which has so far met with a great deal of
excitement and scientific challenge. It is clear that APP
undergoes complex regulation and is important for neu-
ronal and synaptic function. Since genetic mutations in
APP are causal for AD, and abnormal expression of wild-
type APP are linked to AD pathology in Down Syndrome
patients [130] and early-onset AD with cerebral amyloid
angiopathy [131]), it is reasonable to speculate that dis-
turbance of APP-regulated pathways may directly contrib-
ute to neuronal and synaptic impairment and disease
pathogenesis in an Aβ-dependent or Aβ-independent
manner. As such, a more complete understanding of AD
pathogenesis will likely require greater insights into the
physiological functions of APP.
Abbreviations
AD, Alzheimer's disease; APP: amyloid precursor protein;
APLP1: APP-like protein 1; APLP2: APP-like protein 2; Aβ,
β-amyloid; EC: extracellular; IC: intracellular; TM: trans-
membrane; AICD: APP intracellular domain; CTF: car-
boxyl terminal fragment; KLC: kinesin light chain; NMJ:
neuromuscular junction.
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